Victory Capital Management
SNNA

Victory Capital Management’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Victory Capital Management’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,661
Closed -$1K – 3723
2019
Q3 		$1K Sell
3,661
-760,949
-100% -$515K ﹤0.01% 3753
2019
Q2 		$665K Sell
764,610
-35,390
-4% -$55.4K ﹤0.01% 1351
2019
Q1 		$1.86M Buy
+800,000
New +$2.17M ﹤0.01% 1099
2018
Q4 		– Sell
-509,690
Closed -$7.55M – 1834
2018
Q3 		$7.55M Buy
509,690
+19,800
+4% +$315K 0.02% 802
2018
Q2 		$7.44M Buy
489,890
+19,560
+4% +$332K 0.02% 798
2018
Q1 		$8.83M Sell
470,330
-9,710
-2% -$170K 0.02% 767
2017
Q4 		$8.71M Buy
480,040
+21,700
+5% +$459K 0.02% 758
2017
Q3 		$10.2M Buy
+458,340
New +$10.1M 0.02% 719

Other funds holding SNNA

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PO
Private Ocean San Rafael, California $1.13B AUM 11.01% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Victory Capital Management's SNNA Position: Q4 2019 in Review

Victory Capital Management sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q4 2019, closing a stake of 3,661 shares — an estimated $1K sold.

Victory Capital Management first reported a position in SNNA in Q3 2017 and held it in 8 quarters. The position peaked at $10.2M in Q3 2017. 4 funds tracked by Wall St. Rank hold SNNA as of Q4 2019.

  • Victory Capital Management reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Victory Capital Management sold 3,661 Sienna Biopharmaceuticals, Inc. shares in Q4 2019, an estimated $1K.
  • Victory Capital Management first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 8 quarters.
  • Victory Capital Management's Sienna Biopharmaceuticals, Inc. position peaked at $10.2M in Q3 2017.
  • 4 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q4 2019.

Based on Victory Capital Management's 13F filing for Q4 2019, filed 4 Feb 2020.